Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1989 Feb;48(2):166–169. doi: 10.1136/ard.48.2.166

Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis.

H L Staub 1, E N Harris 1, M A Khamashta 1, G Savidge 1, W H Chahade 1, G R Hughes 1
PMCID: PMC1003707  PMID: 2494957

Abstract

Most patients with lupus anticoagulant (LA) activity have coincident antibodies to a group of negatively charged phospholipids, and its is suggested that LA and anticardiolipin tests detect antibodies with overlapping specificities. Some discordance between the two assays has been described, however. One patient presenting with severe thrombotic disease (recurrent deep vein thrombosis, pulmonary embolism, inferior venocaval obstruction, myocardial infarction, and digital gangrene) showed strong LA activity in February 1987. An enzyme linked immunosorbent assay (ELISA) showed no binding to the negatively charged phospholipids cardiolipin, phosphatidylserine, and phosphatidic acid, but binding to zwitterionic phosphatidylethanolamine (PE) was demonstrated. Inhibition studies and affinity purification confirmed this finding. Interestingly, the serum did not bind to the kaolin cephalin clotting time reagent when used as antigen in an ELISA. The pathogenic significance of anti-PE antibodies and their relation to LA remains to be clarified. Further studies of the occurrence of anti-PE antibodies in patients with LA activity who have negative anticardiolipin tests are suggested.

Full text

PDF
166

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gharavi A. E., Harris E. N., Asherson R. A., Hughes G. R. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis. 1987 Jan;46(1):1–6. doi: 10.1136/ard.46.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Griffin J. H., Evatt B., Zimmerman T. S., Kleiss A. J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981 Nov;68(5):1370–1373. doi: 10.1172/JCI110385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Harris E. N., Chan J. K., Asherson R. A., Aber V. R., Gharavi A. E., Hughes G. R. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986 Nov;146(11):2153–2156. [PubMed] [Google Scholar]
  4. Harris E. N., Gharavi A. E., Boey M. L., Patel B. M., Mackworth-Young C. G., Loizou S., Hughes G. R. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983 Nov 26;2(8361):1211–1214. doi: 10.1016/s0140-6736(83)91267-9. [DOI] [PubMed] [Google Scholar]
  5. Harris E. N., Gharavi A. E., Hughes G. R. Anti-phospholipid antibodies. Clin Rheum Dis. 1985 Dec;11(3):591–609. [PubMed] [Google Scholar]
  6. Harris E. N., Gharavi A. E., Tincani A., Chan J. K., Englert H., Mantelli P., Allegro F., Ballestrieri G., Hughes G. R. Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol. 1985 Aug;17(4):155–162. [PubMed] [Google Scholar]
  7. Hughes G. R. The anticardiolipin syndrome. Clin Exp Rheumatol. 1985 Oct-Dec;3(4):285–286. [PubMed] [Google Scholar]
  8. Hughes G. R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1088–1089. doi: 10.1136/bmj.287.6399.1088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. PROCTOR R. R., RAPAPORT S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961 Sep;36:212–219. doi: 10.1093/ajcp/36.3.212. [DOI] [PubMed] [Google Scholar]
  10. Pengo V., Thiagarajan P., Shapiro S. S., Heine M. J. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood. 1987 Jul;70(1):69–76. [PubMed] [Google Scholar]
  11. Rosner E., Pauzner R., Lusky A., Modan M., Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost. 1987 Apr 7;57(2):144–147. [PubMed] [Google Scholar]
  12. Shapiro S. S., Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb. 1982;6:263–285. [PubMed] [Google Scholar]
  13. Thiagarajan P., Shapiro S. S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980 Sep;66(3):397–405. doi: 10.1172/JCI109869. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES